# A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

> **NCT03395210** · PHASE2 · COMPLETED · sponsor: **Principia Biopharma, a Sanofi Company** · enrollment: 86 (actual)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Rilzabrutinib

## Key facts

- **NCT ID:** NCT03395210
- **Lead sponsor:** Principia Biopharma, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-22
- **Primary completion:** 2023-01-31
- **Final completion:** 2025-12-11
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03395210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03395210, "A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03395210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*